Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
76.6M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
42.6M
-
Shares change
-
-2.92M
-
Total reported value, excl. options
-
$555M
-
Value change
-
-$36.7M
-
Number of buys
-
67
-
Number of sells
-
-28
-
Price
-
$13.03
Significant Holders of Nurix Therapeutics, Inc. - Common Stock (NRIX) as of Q3 2022
121 filings reported holding NRIX - Nurix Therapeutics, Inc. - Common Stock as of Q3 2022.
Nurix Therapeutics, Inc. - Common Stock (NRIX) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 42.6M shares
of 76.6M outstanding shares and own 55.55% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (3.88M shares), BlackRock Inc. (3.72M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.61M shares), Redmile Group, LLC (3.01M shares), WASATCH ADVISORS INC (2.66M shares), STATE STREET CORP (2.31M shares), VANGUARD GROUP INC (2.16M shares), Deep Track Capital, LP (2.05M shares), Bain Capital Life Sciences Investors, LLC (1.82M shares), and FMR LLC (1.69M shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.